Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis
NCT05275647 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2022-03-25
Summary
Low energy shock wave (LESW) is known to facilitate tissue regeneration with analgesic and anti-inflammatory effects. LESW treatment has been demonstrated effective in treatment of nonbacterial prostatitis and chronic pelvic pain syndrome. LESW reduced pain behavior and down-regulated the NGF expression, suppressed bladder overactivity by decreasing inflammation, IL-6 and COX2 expression and NGF expression. Previous rat interstitial cystitis (IC) models have shown LESW could increase urothelial permeability, facilitate intravesical botulinum toxin A (BoNT-A) delivery and block acetic acid induced hyperactive bladder, suggesting LESW might be a potential therapeutic candidate for relieving bladder inflammatory conditions and overactivity. A double-blind, randomized, placebo-controlled physician-initiated study revealed LESW treatment was associated with a statistically significant decrease in O'Leary-Saint Symptom Score and visual analog scale of pain in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), but the improvement was not superior to the sham LESW treatment. Previous studies found the urothelial dysfunction and deficits of cell differentiation are fundamental pathophysiology of IC/BPS. Through intravesical platelet-rich plasma injections, the chronic inflammation in IC/BPS bladders could be reduced and improved cell differentiation of urothelium. Botox injection or liposome encapsulated Botox could also inhibit inflammation and improve IC/BPS symptoms. However, the Botox injection needs anesthesia and certain complications might occur. There is no study to test if LESW plus Botox intravesical instillation could improve bladder inflammation and relieve IC/BPS symptoms. This study aims to investigate the therapeutic efficacy and safety of concomitant LESW plus intravesical BoNT-A instillation for IC/BPS refractory to conventional treatments.
Conditions
- Interstitial Cystitis
Interventions
- DRUG
-
BOTOX 100U in normal saline
LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
- DRUG
-
Normal saline
LESW treatment with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical instillation of 30ml normal saline retained in the bladder for 2 hours after LESW application, every one week for 4 times.
Sponsors & Collaborators
-
Ministry of Science and Technology, Taiwan
collaborator OTHER_GOV -
Hualien Tzu Chi General Hospital
collaborator OTHER -
Buddhist Tzu Chi General Hospital
lead OTHER
Principal Investigators
-
Hann-Chorng Kuo, M.D. · Department of Urology, Buddhist TzuChi General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-18
- Primary Completion
- 2024-07-31
- Completion
- 2024-09-30
Countries
- Taiwan
Study Locations
More Related Trials
-
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
NCT01997983 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
NCT02297100 ·Status: COMPLETED ·Phase: PHASE4
-
Botox as a Treatment for Interstitial Cystitis in Women
NCT00194610 ·Status: COMPLETED ·Phase: PHASE4
-
Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding
NCT01733290 ·Status: COMPLETED ·Phase: PHASE2
-
Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
NCT01042119 ·Status: COMPLETED
-
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
NCT05141006 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
NCT05968885 ·Status: RECRUITING ·Phase: PHASE4
-
Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome
NCT01657409 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.
NCT02524236 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)
NCT02786407 ·Status: UNKNOWN ·Phase: PHASE3
-
Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome
NCT01157507 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
NCT01107392 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions
NCT01437579 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
NCT00578097 ·Status: TERMINATED ·Phase: PHASE2
-
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
NCT01502956 ·Status: COMPLETED ·Phase: PHASE3
-
TENS Used for Pain Management During Office Cystoscopy Botox Injections
NCT04448171 ·Status: TERMINATED ·Phase: NA
-
516-BOTOX Urinary Incontinence Detrusor
NCT00850733 ·Status: COMPLETED
-
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
NCT01220726 ·Status: COMPLETED ·Phase: PHASE3
-
Intra-muscular Botulinum Toxin A in Chronic Athletic Pubalgia
NCT05430893 ·Status: COMPLETED
-
Botulin-A Toxin Instillations and Overactive Bladder
NCT00583219 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trigonal vs Non Trigonal Botox Injection in OAB.
NCT03533062 ·Status: COMPLETED ·Phase: NA
-
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
NCT02601287 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
NCT00461292 ·Status: COMPLETED ·Phase: PHASE3
-
This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
NCT00479596 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
NCT01682603 ·Status: COMPLETED ·Phase: PHASE2